KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBT (2016 - 2025)

Ionis Pharmaceuticals has reported EBT over the past 17 years, most recently at $153.3 million for Q4 2025.

  • Quarterly results put EBT at $153.3 million for Q4 2025, up 242.33% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 100.34% YoY), and the annual figure for FY2025 was $1.6 million, up 100.34%.
  • EBT for Q4 2025 was $153.3 million at Ionis Pharmaceuticals, up from -$128.4 million in the prior quarter.
  • Over the last five years, EBT for IONS hit a ceiling of $224.9 million in Q4 2021 and a floor of -$146.8 million in Q1 2025.
  • Median EBT over the past 5 years was -$82.2 million (2021), compared with a mean of -$54.0 million.
  • Biggest five-year swings in EBT: surged 1404.39% in 2021 and later tumbled 3791.69% in 2024.
  • Ionis Pharmaceuticals' EBT stood at $224.9 million in 2021, then plummeted by 119.71% to -$44.3 million in 2022, then surged by 93.76% to -$2.8 million in 2023, then tumbled by 3791.69% to -$107.7 million in 2024, then surged by 242.33% to $153.3 million in 2025.
  • The last three reported values for EBT were $153.3 million (Q4 2025), -$128.4 million (Q3 2025), and $123.5 million (Q2 2025) per Business Quant data.